Showing results (121-130 of 280) with videos related to
Sort By:
Pageof 28
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.Epigenetics|March 21, 2015
Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenograftsPragya Srivastava, Benjamin E Paluch, Junko Matsuzaki, et al.Cold Spring Harbor Molecular Case Studies|July 11, 2023
Evaluation of hypereosinophilia in a case of <i>FLT3</i>-mutant acute myeloid leukemia treated with gilteritinibLeslie N Martinez-Gutierrez, Blake C Burgher, Manuel J Glynias, et al.European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaGuillermo Garcia-Manero, Steven D Gore, Christopher Cogle, et al.Scientific Reports|December 3, 2021
Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United StatesAbhay Singh, Megan M Herr, Elizabeth A Griffiths, et al.Cancer|September 5, 2019
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysisAmer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E DeZern, Anthony Sung, Sharon Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid LeukemiaMonica R Muppidi, Scott Portwood, Elizabeth A Griffiths, et al.Pageof 28